JP2013522313A - 抗神経成長因子（ｎｇｆ）抗体組成物 - Google Patents

抗神経成長因子（ｎｇｆ）抗体組成物 Download PDF

Info

Publication number
JP2013522313A
JP2013522313A JP2013500181A JP2013500181A JP2013522313A JP 2013522313 A JP2013522313 A JP 2013522313A JP 2013500181 A JP2013500181 A JP 2013500181A JP 2013500181 A JP2013500181 A JP 2013500181A JP 2013522313 A JP2013522313 A JP 2013522313A
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
ngf
composition according
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522313A5 (cg-RX-API-DMAC7.html
Inventor
フラウンホーフアー，ボルフガング
チヤーリ，ラビ
クマール，ビニート
ザーエドラー，ライナー
ジードラー，ミヒヤエル
スタイン，ウイリアム・ビー
ベーバー，カルステン
Original Assignee
アボツト・リサーチ・ベー・フエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44114427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013522313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アボツト・リサーチ・ベー・フエー filed Critical アボツト・リサーチ・ベー・フエー
Publication of JP2013522313A publication Critical patent/JP2013522313A/ja
Publication of JP2013522313A5 publication Critical patent/JP2013522313A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2013500181A 2010-03-17 2011-03-16 抗神経成長因子（ｎｇｆ）抗体組成物 Pending JP2013522313A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31498410P 2010-03-17 2010-03-17
US61/314,984 2010-03-17
PCT/US2011/028659 WO2011116090A1 (en) 2010-03-17 2011-03-16 Anti-nerve growth factor (ngf) antibody compositions

Publications (2)

Publication Number Publication Date
JP2013522313A true JP2013522313A (ja) 2013-06-13
JP2013522313A5 JP2013522313A5 (cg-RX-API-DMAC7.html) 2014-05-01

Family

ID=44114427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500181A Pending JP2013522313A (ja) 2010-03-17 2011-03-16 抗神経成長因子（ｎｇｆ）抗体組成物

Country Status (25)

Country Link
US (1) US20110256135A1 (cg-RX-API-DMAC7.html)
EP (1) EP2547365A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013522313A (cg-RX-API-DMAC7.html)
KR (1) KR20130031247A (cg-RX-API-DMAC7.html)
CN (1) CN102892430A (cg-RX-API-DMAC7.html)
AR (1) AR080685A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011227335B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012023895A2 (cg-RX-API-DMAC7.html)
CA (1) CA2790699A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002536A1 (cg-RX-API-DMAC7.html)
CO (1) CO6640289A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120490A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000246A (cg-RX-API-DMAC7.html)
EC (1) ECSP12012211A (cg-RX-API-DMAC7.html)
GT (1) GT201200258A (cg-RX-API-DMAC7.html)
MX (1) MX2012010728A (cg-RX-API-DMAC7.html)
NZ (1) NZ602054A (cg-RX-API-DMAC7.html)
PE (1) PE20130203A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501761A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012144017A (cg-RX-API-DMAC7.html)
SG (2) SG183983A1 (cg-RX-API-DMAC7.html)
TW (1) TW201201835A (cg-RX-API-DMAC7.html)
UY (1) UY33280A (cg-RX-API-DMAC7.html)
WO (1) WO2011116090A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201206761B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX2015012549A (es) * 2013-03-15 2016-06-21 Abbvie Deutschland Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN111402950B (zh) * 2013-11-29 2024-03-19 豪夫迈·罗氏有限公司 抗体选择装置和方法
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
MX2018011675A (es) * 2016-03-25 2019-01-10 Astellas Pharma Inc Composicion farmaceutica que comprende un fragmento fab' pegilado de anticuerpo anti-ngf humano.
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
IT201800009384A1 (it) 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
GB2579707A (en) 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CA3094194A1 (en) * 2019-03-26 2020-09-26 Remegen Co., Ltd. Pharmaceutical formulations of her2 antibody-drug conjugate
CN111939267B (zh) * 2019-05-17 2024-12-20 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
KR102265434B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
SI4076385T1 (sl) * 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
US11492394B1 (en) * 2021-10-29 2022-11-08 Nascent Biotech, Inc. Kits and containers for treating vimentin expressing tumors
WO2025077862A1 (zh) * 2023-10-12 2025-04-17 舒泰神（北京）生物制药股份有限公司 一种NGF-Fc融合蛋白制剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538287A (ja) * 2001-07-25 2004-12-24 プロテイン デザイン ラブス インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
JP2008542439A (ja) * 2005-06-07 2008-11-27 パンジェネティックス ベースローテン フェンノートシャップ ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2975521A1 (en) 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
AR045056A1 (es) 2003-07-15 2005-10-12 Amgen Inc Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
EP2298345A3 (en) 2005-01-24 2012-03-21 MedImmune Limited Specific binding members for NGF
MX2008016335A (es) 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
PT2331090T (pt) * 2008-09-19 2018-02-07 Pfizer Formulação de anticorpo líquida estável
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538287A (ja) * 2001-07-25 2004-12-24 プロテイン デザイン ラブス インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
JP2008542439A (ja) * 2005-06-07 2008-11-27 パンジェネティックス ベースローテン フェンノートシャップ ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor

Also Published As

Publication number Publication date
SG10201504808XA (en) 2015-07-30
MX2012010728A (es) 2013-03-05
KR20130031247A (ko) 2013-03-28
UY33280A (es) 2011-10-31
BR112012023895A2 (pt) 2016-11-29
US20110256135A1 (en) 2011-10-20
AU2011227335B2 (en) 2014-11-06
NZ602054A (en) 2014-10-31
ECSP12012211A (es) 2012-10-30
SG183983A1 (en) 2012-10-30
AU2011227335A1 (en) 2012-09-20
AR080685A1 (es) 2012-05-02
CN102892430A (zh) 2013-01-23
PE20130203A1 (es) 2013-03-24
CL2012002536A1 (es) 2012-12-07
WO2011116090A1 (en) 2011-09-22
RU2012144017A (ru) 2014-04-27
EP2547365A1 (en) 2013-01-23
CR20120490A (es) 2013-04-09
CA2790699A1 (en) 2011-09-22
PH12012501761A1 (en) 2012-11-12
DOP2012000246A (es) 2012-11-15
CO6640289A2 (es) 2013-03-22
ZA201206761B (en) 2013-05-29
GT201200258A (es) 2014-02-21
TW201201835A (en) 2012-01-16

Similar Documents

Publication Publication Date Title
AU2011227335B2 (en) Anti-nerve growth factor (NGF) antibody compositions
CN111971062B (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2023109942A (ja) 単独およびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
JP5623743B2 (ja) 安定なポリペプチド製剤
JP7475335B2 (ja) Ｃｓｆ－１ｒ抗体製剤
KR20120110175A (ko) 항체 제제
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
CA2949212A1 (en) Antibody formulation
TW202104270A (zh) 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途
KR20150095684A (ko) 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
CN113194925B (zh) 抗体制剂
TW201542226A (zh) 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
CN113453719A (zh) 包含抗cd47抗体的制剂及其制备方法和用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
TWI836069B (zh) 抗-sema3a抗體及其用於治療眼或眼部疾病之用途
JP2025142195A (ja) 抗ｐｄ－１／ｈｅｒ２二重特異性抗体を含む製剤及びその調製方法と使用
CN111683681B (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
JP2025519600A (ja) 抗ｉｇｆ－１ｒ抗体組成物
JP2025519612A (ja) Ｉｇｆ１ｒ抗体
CN116440263A (zh) 抗ctla-4抗体药物组合物及其用途
TW202126685A (zh) 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
RU2829156C2 (ru) Композиция, содержащая анти-pd-1/her2 биспецифическое антитело, способ ее получения и ее использование
HK40118051A (zh) Csf-1r抗体制剂
HK40052133A (en) Csf-1r antibody formulation
HK40107164A (zh) Csf-1r抗体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151104